Performance Forecast - The company expects a net profit of approximately 9 million yuan for the current reporting period, a decrease of about 59.81% compared to the same period last year, which was 22.39 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be around 1.6 million yuan, down approximately 93.40% from 24.25 million yuan in the previous year [1] - Basic earnings per share are projected to be about 0.02 yuan, compared to 0.04 yuan in the same period last year [1] Reasons for Performance Changes - The decline in net profit is attributed to decreased transportation demand, increasing penetration of new and alternative energy sources, and intensified competition in the refined oil industry, leading to a reduction in the price difference and sales volume of refined oil [1] - The company is undergoing a transformation in its trading business, with a contraction in chemical product trading and an overall decline in chemical product sales [1] - The company reported non-recurring gains of approximately 7.4 million yuan, a significant increase of about 497.91% compared to a loss of 1.86 million yuan in the previous year, primarily due to increased gains from the disposal of trading financial assets and changes in fair value [2]

Core Viewpoint - The article highlights the involvement of a Chinese organization in the illegal trafficking of synthetic drugs, particularly fentanyl, with connections to Japan and the United States, raising concerns about international drug smuggling networks [1][12][20]. Group 1: Arrests and Investigations - In June 2023, the U.S. Drug Enforcement Administration (DEA) arrested Chinese nationals Wang Qingzhou and Chen Yiyi for allegedly smuggling dangerous drugs into the U.S. [1][3] - During the investigation, a figure referred to as "the boss in Japan," identified as Fengzhi Xia, emerged, indicating a potential leadership role in the drug trafficking organization [1][5][12]. Group 2: Company Connections - Wang Qingzhou and others were executives at Hubei Amarvel Biotech, a chemical company in Wuhan, which was found guilty of illegally importing fentanyl precursors into the U.S. [5][12] - Chen Yiyi confirmed her employment at companies invested by Fengzhi Xia, suggesting a network of businesses involved in the drug trade [5][12]. Group 3: Social Media and Identification - Investigations revealed a Facebook account belonging to Fengzhi Xia, with limited connections and a profile indicating residence in Naha, Japan, but with ties back to Wuhan [5][9][11]. - The article notes that Xia is linked to at least 16 companies across China, including a 100% owned trading company in Wuhan, indicating a broad network of operations [9][12]. Group 4: Drug Trafficking Routes - The article discusses the emergence of Japan as a potential hub for drug trafficking, with experts indicating multiple smuggling routes involving Japan, Mexico, and the U.S. [14][16]. - FIRSKY, a company linked to Xia, is noted to have operations in Japan and is involved in the import-export of chemical products, further complicating the drug trafficking landscape [10][12]. Group 5: Fentanyl Crisis in the U.S. - The article emphasizes the severity of the fentanyl crisis in the U.S., with approximately 110,000 overdose deaths in 2023, primarily due to synthetic opioids like fentanyl [13][20]. - The DEA has been monitoring Amarvel since 2022, revealing a complex network for fentanyl distribution from China to Mexico and then to the U.S. [18][20].